NCNA
NuCana plc
NASDAQ · Healthcare · Biotechnology · GB
$1.40
−2.10%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 71.4K | — | — | — | — |
| Gross Profit | (71.4K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 9.4M | 12.7M | 18.0M | 25.1M | 36.4M |
| SG&A Expense | 5.2M | 8.1M | 5.0M | 6.1M | 7.3M |
| General & Admin Expense | 4.1M | 8.1M | 5.0M | 6.1M | 7.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (1.3M) | (723.0K) | (196.0K) | 1.7M | (4.6M) |
| Total Operating Expenses | 13.2M | 20.1M | 22.8M | 32.8M | 39.1M |
| Cost and Expenses | 13.3M | 20.1M | 22.8M | 32.8M | 39.1M |
| Operating Income (EBIT) | (13.3M) | (20.1M) | (22.8M) | (32.8M) | (39.1M) |
| Non-Operating | |||||
| Interest Income | 603.7K | 386.0K | 358.0K | 754.0K | 669.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 603.7K | 386.0K | 358.0K | 754.0K | 669.0K |
| Other Non-Op Income/Expense | 2.3M | (10.4M) | 358.0K | 754.0K | 669.0K |
| Non-Operating Income (excl Interest) | 1.3M | 723.0K | 196.0K | (1.7M) | 4.6M |
| EBT (Pre-Tax Income) | (11.0M) | (30.5M) | (22.5M) | (32.0M) | (38.5M) |
| Income Tax Expense | (1.2M) | (1.2M) | (3.5M) | (4.4M) | (6.4M) |
| Bottom Line | |||||
| Net Income | (9.7M) | (29.4M) | (19.0M) | (27.6M) | (32.0M) |
| Earnings from Cont. Ops | (9.7M) | (29.4M) | (19.0M) | (27.6M) | (32.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (9.7M) | (29.4M) | (19.0M) | (27.6M) | (32.0M) |
| Per Share | |||||
| Basic EPS | ($2.97) | ($17.20) | ($1,635.98) | ($3,266.68) | ($3,775.53) |
| Diluted EPS | ($2.97) | ($17.20) | ($1,635.98) | ($3,266.68) | ($3,775.53) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 4.2M | 2.2M | 14838 | 10514 | 10447 |
| Diluted Shares Outstanding | 4.2M | 2.2M | 14838 | 10514 | 10447 |
| Profitability Metrics | |||||
| EBITDA | (14.4M) | (20.6M) | (22.5M) | (30.6M) | (43.0M) |
| D&A | 277.4K | 274.0K | 522.0K | 575.0K | 732.0K |
| EBIT | (14.6M) | (20.8M) | (23.0M) | (31.1M) | (43.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026